August 2012
-
Satsuma Pharmaceuticals has initiated the SUMMIT Phase 3 trial of its STS101 dihydroergotamine (DHE) nasal powder for the treatment of migraine, the company said. A previous Phase 3 trial of STS101 called EMERGE failed to… Read more . . .
-
Submit workshop proposals by December 1, 2021 at https://www.rddonline.com/rdd/workshop_reg.php?id=21 Submit poster abstracts by January 21, 2022 at https://www.rddonline.com/rdd/poster_reg.php?id=21 Poster abstracts from graduate students that are accepted for the conference will automatically be entered into competition… Read more . . .
-
Augmenta Bioworks and TFF Pharmaceuticals have announced that in vitro testing of their AUG-3387 dry powder monoclonal antibody has demonstrated that the mAb neutralizes the SARS-CoV-2 Delta variant, the highly transmissible strain that is currently dominant in numerous… Read more . . .
-
According to Lannett, the company has acquired US rights to market Respirents generic of Spiriva Handihaler tiotropium bromide DPI for a 10-year period, the company said. Lannett had already acquired US rights to Respirent’s generic versions… Read more . . .
-
Results from a Phase 1 trial of an inhaled version of CanSino Biologic’s Ad5-nCoV vaccine against COVID-19 have been published online in The Lancet Infectious Diseases. The study enrolled 130 healthy volunteers who got either… Read more . . .
-
Atai Life Sciences and University of Queensland technology transfer company UniQuest have announced the launch of a new company called InnarisBio, which will develop intranasal drug delivery technology for CNS drugs based on sol-gel technology developed by… Read more . . .
-
Preclinical studies by researchers from the LKS Faculty of Medicine at The University of Hong Kong have demonstrated that a dry powder formulation of tamibarotene delivered to the lungs of hamster and mice has broad… Read more . . .
-
H&T Presspart has acquired Swiss device maker Novelex (formerly Forteq Nidau), the company said, and all Novelex employees will be absorbed into H&T Presspart. The company acquired Novelex from Liberta Partners, which had acquired Forteq… Read more . . .
-
Sorrento Therapeutics has initiated a Phase 2 trial of its CoviDrops intranasal neutralizing antibody in COVID-19 patients in the UK, the company said. The trial is expected to enroll 350 COVID-19 patients who have mild… Read more . . .
-
Esteve Pharmaceuticals has acquired the exclusive rights to market Inbrija dry powder levodopa in Spain and expects to launch the product there by the end of 2022, according to Acorda Therapeutics. Esteve will pay Acorda… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.